- Merck ( NYSE: MRK ) announced Thursday that the federal appeals court handed it a favorable ruling in a patent dispute with Viatris ( NASDAQ: VTRS ) over the generic drugmaker's attempt to market copycat versions of its blockbuster diabetic medications Januvia and Janumet.
- Mylan Pharmaceuticals, currently known as Viatris brought the patent challenge regarding sitagliptin dihydrogen phosphate, the active ingredient of MRK's blockbuster diabetic medications Januvia, Janumet and Janumet XR.
- In May 2021, the U.S. Patent Office ruled in favor of MRK over the validity of U.S. Patent No.7,326,708 following an inter partes review, and VTRS appealed the decision to the Court of Appeals, which reaffirmed the ruling.
- On Sep. 22, MRK said that a U.S. District Court ruled against VTRS in a dispute over two sitagliptin patents.
For further details see:
Merck wins appeals court ruling against Viatris over generic diabetic drugs